There are no other clinical studies of SOAT1 inhibition in ACC ongoing at this time, but several other compounds have been shown to target SOAT1 in preclinical studies, including the SOAT1 inhibitor avasimibe and the BCR-ABL TKI nilotinib.81 These may be of interest in future clinical studies in ACC. Here, ABL1 is linked to adrenal cortex carcinoma.